At a Glance
Vela Diagnostics facts and figures
- Established in 2011
- Approximately 200 employees worldwide
- Pioneer in offering both real-time PCR and Next-Generation Sequencing on an integrated platform.
- More than 30 research or IVD tests in nine disease areas*
- 15 validated sample types
- ISO 13485:2003 certified R&D and manufacturing facilities located in Singapore, with additional R&D facilities in United States
- CLIA-certified laboratory in United States
- Global network with direct operations and distributors across North America, Europe and Asia Pacific
*regulatory status of products is based on regional availability
Select achievements and milestones
2011
- Founding of global head office in Singapore, with regional operations set up in New Jersey, US and Hamburg, Germany
- Distribution agreement with Qiagen and OEM agreement with Eppendorf
- qPCR license with Roche
- OEM agreement with Macherey Nagel
2012
- Start of direct sales in several European markets including Italy, France, UK, Benelux and Scandinavia
- Establishment of qPCR workflows and first CE-IVD tests
- OEM agreement with Life Technologies for NGS solutions
- CLIA lab license in US
- OEM agreement with Swift Biosciences
2013
- Start of direct sales in Australia and Malaysia
- Distribution agreement with AmeriLab for China and Diagnostica Longwood for Spain
2014
- Start of direct sales in Thailand
- NGS license agreement with Appistry
- Launch of the first NGS-based oncology panel for IVD use in Europe and parts of Asia
- Distribution agreement with SurgiTech AS for Estonia
2015
- Direct sales planned for India
2016
-
Licensing agreement with Stanford University for use of HIVdb
- Launch of NGS based HIV assay
-
Acquisition of Lifecode Inc’s data interpretation assets
-
FDA emergency authorization for Zika PCR assay
-
Distribution agreement with Diagen AS in Scandinavia
-
Distribution agreement with DYN Diagnostics in Israel
-
Distribution agreement with Advanced Diagnostics in Myanmar
2017
-
Start of direct sales in Spain
-
CE-IVD and TGA approval for NGS based HIV and HCV assays
-
Distribution agreement with MALVA SA in Greece
2018
-
Licensing agreement with UCSF for FLASH and DASH enrichment technologies
-
US FDA 510(k) clearance for Herpes Simplex virus PCR assay
-
Acquisition of Great Basin Scientific, a former publicly-held, US-based provider of easy-to-use molecular diagnostics for infectious disease
-
Distribution agreement with Lab Depot in Peru
2019
- Thai FDA and SIngapore HSA approval for NGS-based HIV Genotyping Assay
- US FDA De Novo Designation for Sentosa® SQ HIV-1 Genotyping Assay
2020
- Launch of SARS-CoV-2 RT-PCR diagnostic assay
- CE-IVD and HSA Provisional Authorization for ViroKey™ SARS-CoV-2 RT-PCR Test
- BARDA Funding to develop COVID-19 diagnostic assay
- Launch of NGS-based ViroKey™ SQ FLEX Genotyping Assay that detects DRMs in HIV-1, HCV, HBV & CMV